EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Feasibility and tolerability of anlotinib plus PD-1 blockades as rechallenge immunotherapy in previously treated advanced ESCC: a retrospective study

Yonggui Hong, Jun Liu, Ping Lu, Zhiwei Chang, Guifang Zhang, Xiumei Ma, Wei Liang, Yongjing Tian, Jin Xia, Heng Cao, Jing Huang iD

The Oncologist · 2025

DOI: 10.1093/oncolo/oyae245 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, 2025. Verfasst von Yonggui Hong und 10 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology, Anyang Tumor Hospital, Anyang 455000, People's Republic of China. Hauptthemen laut MEDLINE: Indoles, Quinolines, Esophageal Neoplasms, Esophageal Squamous Cell Carcinoma. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Rechallenge with immune checkpoint inhibitor (ICI) seemed favorable in several tumors, but clinical experience on esophageal squamous cell carcinoma (ESCC) was scanty. This real-world study aimed to assess the feasibility and safety of anlotinib plus ICI for patients with previously ICI-treated advanced ESCC. Materials and Methods We retrospectively identified advanced ESCC patients who received anlotinib plus ICI in the rechallenge setting for evaluation of clinical outcomes and safety. Totally 110 ICI-pretreated patients, of which 89 (80.9%) received prior first- or second-line treatment, were included from September 9, 2019, to November 30, 2022. Most patients (63.6%) discontinued initial ICI due to disease progression.

Results

After rechallenge, median overall survival (OS) and progression-free survival (PFS) were 11.1 (95% CI, 8.6-13.7) and 5.6 (95% CI, 4.4-6.8) months, respectively; estimated OS and PFS rates at 12 months were 47.6% (95% CI, 36.8%-57.7%) and 21.4% (95% CI, 10.9%-34.2%), respectively. No complete response was reported and 21 (19.1%) patients attained partial response; the objective response rate was 19.1%. Fifty-five (50.0%) had stable disease for a disease control rate of 69.1%. Of the 21 responders, median duration of response was 6.4 months. Tendencies for longer OS were observed in patients with Eastern Cooperative Oncology Group Performance of 0 (P = .056). The incidence of grade 3 or higher treatment-related adverse events was 10.0%.

Conclusion

Anlotinib plus ICI in the rechallenge setting was promising and resulted in encouraging benefits for patients with previously ICI-treated advanced ESCC. Our findings provided preliminary but unique evidence to help select ESCC patients benefiting from this strategy. Trial registration chictr.org.cn; number ChiCTR2300070777

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IndolesQuinolinesEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaImmune Checkpoint InhibitorsAntineoplastic Combined Chemotherapy ProtocolsImmunotherapyHumansMaleFemaleRetrospective StudiesMiddle AgedAgedFeasibility StudiesAdultProgrammed Cell Death 1 ReceptorAged, 80 and over

Stichwörter der Autor:innen

ICI rechallengeadvanced esophageal squamous cell carcinomaanlotinib plus ICIefficacy and safety

Substanzen

anlotinibIndolesQuinolinesImmune Checkpoint InhibitorsProgrammed Cell Death 1 Receptor

Autor:innen und Institutionen

  • Gastroenterology, Anyang Tumor Hospital, Anyang 455000, People's Republic of China.
  • Radiation Oncology Department, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai 200025, People's Republic of China.
  • Medical Oncology, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang 453100, People's Republic of China.
  • Medical Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, People's Republic of China.
  • Medical Oncology, Xinxiang Central Hospital, Xinxiang 453700, People's Republic of China.
  • Radiation Oncology, Renji Hospital Affiliated to Medical College of Shanghai Jiaotong University, Shanghai 200127, People's Republic of China.

ORCID-Profile: Jing Huang

Zitieren

APA

Hong, Y., Liu, J., Lu, P., Chang, Z., Zhang, G., Ma, X., Liang, W., Tian, Y., Xia, J., Cao, H., & Huang, J. (2025). Feasibility and tolerability of anlotinib plus PD-1 blockades as rechallenge immunotherapy in previously treated advanced ESCC: a retrospective study. The Oncologist. https://doi.org/10.1093/oncolo/oyae245

Vancouver

Hong Y, Liu J, Lu P, Chang Z, Zhang G, Ma X, et al. Feasibility and tolerability of anlotinib plus PD-1 blockades as rechallenge immunotherapy in previously treated advanced ESCC: a retrospective study. The Oncologist. 2025. doi:10.1093/oncolo/oyae245

BibTeX
@article{Hong2025,
  author = {Hong, Yonggui and Liu, Jun and Lu, Ping and Chang, Zhiwei and Zhang, Guifang and Ma, Xiumei and Liang, Wei and Tian, Yongjing and Xia, Jin and Cao, Heng and Huang, Jing},
  title = {Feasibility and tolerability of anlotinib plus PD-1 blockades as rechallenge immunotherapy in previously treated advanced ESCC: a retrospective study},
  journal = {The Oncologist},
  year = {2025},
  doi = {10.1093/oncolo/oyae245}
}
Kostenlos starten →